Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126222011 | 12622201 | 1 | I | 20160727 | 20160804 | 20160804 | EXP | US-MYLANLABS-2016M1031711 | MYLAN | LE N, ROSEN SG. SEVERE ELECTROLYTE ABNORMALITIES AFTER ZOLEDRONIC ACID TREATMENT FOR OSTEOPOROSIS. ENDOCR-REV 2014;35: ABSTR. SUN-0214. | 0.00 | Y | 0.00000 | 20160804 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126222011 | 12622201 | 1 | PS | ZOLEDRONIC ACID | ZOLEDRONIC ACID | 1 | Intravenous (not otherwise specified) | 5 MG | U | U | 202650 | INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126222011 | 12622201 | 1 | Osteoporosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126222011 | 12622201 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126222011 | 12622201 | Hypocalcaemia | |
| 126222011 | 12622201 | Hypokalaemia | |
| 126222011 | 12622201 | Hyponatraemia | |
| 126222011 | 12622201 | Hypophosphataemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |